Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases
: News / Press Releases

News / Press Releases

Latest News

Tonix Pharmaceuticals Announces Licensing Agreement with Columbia University for the Development of Recombinant Trefoil Family Factor 2 (rTFF2), or TNX-1700, for the Treatment of Gastric and Pancreatic Cancers

Read Press Release

Upcoming Event

Ladenburg Thalmann 2019 Healthcare Conference

Sofitel, New York, NY

View Events

Upcoming Event

Sidoti & Company Fall 2019 Investor Conference

Grand Hyatt, New York, NY

View Events

Upcoming Event

2019 NAVREF Conference

San Antonio, Texas

View Events

Recent News